Therapy-related acute leukaemia with Mitoxantrone: what is the risk and can we minimise it?
about
Switching multiple sclerosis patients with breakthrough disease to second-line therapy.The risk of malignancy is not increased in patients with multiple sclerosis treated with subcutaneous interferon beta-la: analysis of data from clinical trial and post-marketing surveillance settings.Toxicities of immunosuppressive treatment of autoimmune neurologic diseases.Therapy-related acute promyelocytic leukemia: a systematic review.A randomized, blinded, parallel-group, pilot trial of mycophenolate mofetil (CellCept) compared with interferon beta-1a (Avonex) in patients with relapsing-remitting multiple sclerosis.Therapeutic strategies in childhood multiple sclerosisChemotherapeutics in the treatment of multiple sclerosis.Results from the 5-year, phase IV RENEW (Registry to Evaluate Novantrone Effects in Worsening Multiple Sclerosis) studyLights and shadows of cyclophosphamide in the treatment of multiple sclerosisGlobal characteristics of childhood acute promyelocytic leukemia.New insights into neuromyelitis opticaMolecular pathogenesis of secondary acute promyelocytic leukemiaIncidence of therapy-related acute leukaemia in mitoxantrone-treated multiple sclerosis patients in GermanyAcute myeloid leukemia developing in patients with autoimmune diseases.Fingolimod in the treatment algorithm of relapsing remitting multiple sclerosis: a statement of the Central and East European (CEE) MS Expert Group.Diagnosis and treatment of multiple sclerosis in pediatric and adolescent patients: current status and future therapies.Acute promyelocytic leukemia: what are the treatment options?EFNS guidelines on diagnosis and management of neuromyelitis optica.A critical appraisal of treatment decisions in multiple sclerosis--old versus new.Management of children with multiple sclerosis.The management of pediatric multiple sclerosis.Latin American algorithm for treatment of relapsing-remitting multiple sclerosis using disease-modifying agents.Management of disease-modifying treatments in neurological autoimmune diseases of the central nervous system.Safety concerns and risk management of multiple sclerosis therapies.Temozolomide-induced myelodysplasia.Comparative study of mitoxantrone efficacy profile in patients with relapsing-remitting and secondary progressive multiple sclerosis.Characteristics and outcome of acute myeloid leukemia in patients with a prior history of autoimmune disease.The management of multiple sclerosis in children: a European view.Epidemiology in multiple sclerosis has had its day: there are no more unanswered questions--no.Current therapeutic options in pediatric multiple sclerosis.[Current aspects of therapy conversion for multiple sclerosis].
P2860
Q33815455-B5371195-726B-4FA6-BC46-48D78811F574Q33870816-F31577C1-F6E1-479A-8A68-5EAE812242C5Q34257903-1F13A36A-4DEE-4BCB-AD0C-0DF3757E641AQ34351253-84FF778C-248F-46F0-AD08-ADD54453E9AFQ34409297-0EB8CDDD-F445-49F8-B935-EF476F5D59AAQ34409508-BF7339C6-6872-4FD0-8624-B07CB9FE2599Q34409536-E69B3F9E-B9BF-4729-8173-F571D29CAFDBQ34810005-C3AA3047-24B6-44A6-8B34-BA07A234A84AQ34922742-3DFC1211-C04D-4F1A-838B-C8F3888E07CBQ35231673-5A6BD145-C26D-4418-9A87-15438A1B62FCQ35539641-E96E2EFE-DA8A-4F81-80AB-91A08B69736DQ35560260-DE6BDA17-E0D1-4E23-9CD0-1881523D48AAQ35825923-00FB94C4-329D-42A7-A740-ED8728C0FE55Q36006358-8C7EE9BC-A2AD-40D1-8C88-B8845D548F36Q36223650-91043C92-45E8-4E61-A601-AE04DC31AF52Q37562166-C0E1DA51-31CE-45A6-92BB-02AF1A23488DQ37693929-99F3B77A-E5FD-47A0-B9A7-305D3AD13FC3Q37763266-3433D61E-05AB-4EAC-9AF5-43B6D39DEAD6Q37862062-3B6A3D16-B93E-4FA2-B6AC-F29AB3F2231CQ38002113-B112008A-6CB2-4043-A364-77757440546BQ38036853-A22128F7-51EF-4A58-8AB8-B848ECE89BF4Q38051577-7CF4F4DE-61DF-468C-97F8-762F5090BF5DQ38172961-26A7B6C5-1CEB-40A6-9BE3-68FBB17C6DBEQ39021781-BEAF9910-8537-4781-A1E9-A80997FF7B68Q39442527-7F8D9E2B-1458-416A-BF90-FE826F2D4429Q42920232-36A99927-093F-45AC-AB1F-417ED1DD04E5Q43659778-418CE75F-7C0C-4817-99A7-FCEEAB56B431Q45108726-F144165F-B044-4C8A-9A6F-8AB0D9F0EE83Q48765436-60FE080F-1877-46F3-86A2-79F3E27AE0B1Q48805758-FD94D6E6-C0BC-4B3A-81E9-A7FACDB16D04Q53582374-F2703F63-11C9-4024-93E6-724E41A3E82B
P2860
Therapy-related acute leukaemia with Mitoxantrone: what is the risk and can we minimise it?
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Therapy-related acute leukaemi ...... e risk and can we minimise it?
@en
Therapy-related acute leukaemi ...... e risk and can we minimise it?
@nl
type
label
Therapy-related acute leukaemi ...... e risk and can we minimise it?
@en
Therapy-related acute leukaemi ...... e risk and can we minimise it?
@nl
prefLabel
Therapy-related acute leukaemi ...... e risk and can we minimise it?
@en
Therapy-related acute leukaemi ...... e risk and can we minimise it?
@nl
P2860
P356
P1476
Therapy-related acute leukaemi ...... e risk and can we minimise it?
@en
P2093
P2860
P304
P356
10.1177/1352458508100967
P577
2009-02-27T00:00:00Z